Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.51 |
| ▸ | CLK1 | P49759 | 2/20 | 0.51 |
| ▸ | CLK2 | P49760 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PRUNE1 | Q86TP1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ASPH | Q12797 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20305447 | 0.88 | CLK4 (0.52) | CLK4CLK1CLK2DYRK1ADYRK1B | |
| SCHEMBL30677216 | 0.85 | NPC1 (0.49) | CLK4CLK1CLK2DYRK1ADYRK1B | |
| SCHEMBL19641389 | 0.85 | NPC1 (0.49) | CLK4CLK1CLK2DYRK1ADYRK1B | |
| SCHEMBL27082731 | 0.81 | CLK4 (0.50) | CLK4CLK1CLK2DYRK1ADYRK1B | |
| SCHEMBL27082684 | 0.81 | CLK4 (0.50) | CLK4CLK1CLK2DYRK1ADYRK1B | |
| SCHEMBL30133420 | 0.81 | CLK4 (0.50) | CLK4CLK1CLK2DYRK1ADYRK1B | |
| SCHEMBL30835347 | 0.81 | CLK4 (0.50) | CLK4CLK1CLK2DYRK1ADYRK1B | |
| SCHEMBL26920300 | 0.80 | CLK4 (0.49) | CLK4CLK1CLK2DYRK1ADYRK1B | |
| SCHEMBL18168568 | 0.78 | CCNE2 (0.53) | CLK4CLK1CLK2DYRK1ADYRK1B | |
| SCHEMBL19641279 | 0.78 | NPC1 (0.50) | CLK4CLK1CLK2DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| CN-112351780-B | Substituted heterocyclic inhibitors of PTPN11 | 纳维尔制药有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-13 | — | — | US | disclosed |
| US-11466017-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3463343-B1 | HETEROCYCLIC INHIBITORS OF PTPN11 | UNIV TEXAS (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20210317122-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | Cantero Therapeutics, Inc. | 2021-10-14 | — | — | US | disclosed |
| CN-109475531-B | Heterocyclic inhibitors of PTPN11 | 得克萨斯州立大学董事会 | 2021-08-17 | — | — | CN | disclosed |
| US-10954243-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| CN-112351780-A | Substituted heterocyclic inhibitors of PTPN11 | 纳维尔制药有限公司 | 2021-02-09 | — | — | CN | disclosed |
| US-20210017182-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-01-21 | — | — | US | disclosed |
| US-10851110-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190270746-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-09-05 | — | — | US | disclosed |
| US-10280171-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3463343-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | Board of Regents, University of Texas System (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2018119387-A1 | SMALL MOLECULE INHIBITORS OF COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) AND USES THEREOF | TESARO, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2017210134-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | CLK4 4114/4885CLK1 3234/4885CLK2 2296/4885 |
| US-11466017-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | CLK4 4114/4885CLK1 3234/4885CLK2 2296/4885 |
| US-20210017182-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | CLK4 4114/4885CLK1 3234/4885CLK2 2296/4885 |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | CLK4 4114/4885CLK1 3234/4885CLK2 2296/4885 |
| US-10851110-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | CLK4 4114/4885CLK1 3234/4885CLK2 2296/4885 |
| US-10954243-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | CLK4 4230/4885CLK1 3487/4885CLK2 2459/4885 |
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | CLK4 4230/4885CLK1 3487/4885CLK2 2459/4885 |
| US-20190270746-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | CLK4 4114/4885CLK1 3234/4885CLK2 2296/4885 |
| US-10280171-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | CLK4 4114/4885CLK1 3234/4885CLK2 2296/4885 |
| US-20210317122-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | PTPN11, PTPRJ, PTPRCAP | CLK4 4230/4885CLK1 3487/4885CLK2 2459/4885 |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | CLK4 4114/4885CLK1 3234/4885CLK2 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.